Navigation Links
Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
Date:9/25/2008

The in vivo results of QPI-1007 mark a new era for Quark. We can now rely solely on internally-developed novel compositions and proprietary siRNA structures to develop products that have the potential to provide greater efficacy than current treatments. The breadth of our new structures allows us to selectively pick the most efficacious, stable siRNA structure, which is the most suitable for the specific sequence."

Dr. Logan stated, "QPI-1007 displayed significant neuroprotective activity compared to untreated controls and two different control siRNA molecules in our in vivo model. These results are very exiting. They show that QPI-1007 is a promising drug for ocular neuroprotection."

Dr. Di Polo commented, "The characteristic visual field changes and loss of vision in glaucoma are caused by the selective degeneration of retinal ganglion cells. Our results suggest that QPI-1007 may be an effective neuroprotective therapy for retinal ganglion cells in acute injuries such as non-artheritic ischemic optic neuropathy, and also in slow-progressing chronic optic nerve injuries such as glaucoma. QPI-1007 has the potential to serve an unmet medical need for these indications."

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability to deliver siRNA non invasively to target tissues including the eye, ear, kidney, lung, spinal cord and brain.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified, siRNA molecule to inhibit the expression of the gene RTP801, licensed to Pfizer. In
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 /PRNewswire-iReach/ -- Market Research Report on Global ... a professional and in-depth market survey on ... The report firstly reviews the basic information of ... manufacturing technology. The report then explores global and ... their product specification, capacity, Production value, and market ...
(Date:8/29/2014)... 29, 2014 Pomerantz LLP has filed a ... "Company") (NASDAQ: EDAP ) and certain of ... District Court, Southern District of New York ... of a class consisting of all persons or entities ... July 30, 2014, inclusive (the "Class Period"). This class action ...
(Date:8/29/2014)... Aug. 29, 2014  BC Technical, the nation,s leading ... Medical Imaging, a leader in sales, service and installation ... allows BC Technical to continue to expand their resources ... and CT modalities. "We are committed ... Mark Alvarez , president and CEO of BC Technical. ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3BC Technical Acquires Polaris Medical Imaging 2
... 2012   CareFusion today announced an agreement to ... that helps hospital pharmacies better manage inventory, reduce pharmaceutical ... not disclosed. The acquisition will advance CareFusion,s ... to manage medication throughout their facilities – from ...
... March 6, 2012 Life Length, the ... Drs Sandy Chang and Kathleen Collins have joined its ... CEO, Life Length, noted, "We are delighted to welcome ... SAB. They will help advance our global leadership.  Dr ...
Cached Medicine Technology:CareFusion To Acquire Pharmacy Automation Technology Leader 2CareFusion To Acquire Pharmacy Automation Technology Leader 3CareFusion To Acquire Pharmacy Automation Technology Leader 4Drs Sandy Chang and Kathleen Collins Join LIFE LENGTH®'s Scientific Advisory Board 2
(Date:8/30/2014)... Market Research Report on Global and ... and in-depth market survey on Global and Chinese ... basic information of Cell Disruptor including its classification, ... global and China’s top manufacturers of Cell Disruptor ... market share etc. The report further analyzes quantitatively ...
(Date:8/30/2014)... Continuing to meet the skin health needs ... addition of a new doctor and office in Grand ... skin care in Grand Rapids since 1980 is merging ... doctor, my passion is making sure my patients receive ... I’m better able to focus on my patients and ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 "My wife ... of a car accident," said one of two inventors ... strain in her shoulder and neck area. She tried ... reduced pain and pressure, assisting in comfort and providing ... patent-pending PILLOW CRADLE to support the head, neck and ...
(Date:8/30/2014)... Serving contented clients since inception, #1 web design ... is now offering discount for Labor Day on all ... putting forward the best of web development technology before ... of professionals and web developers and designers has expertise ... critical issues of web development and can develop websites ...
(Date:8/30/2014)... Saturday 30 August 2014: Transvenous lead extraction (TLE) ... according to data from the European Lead Extraction ConTRolled ... ESC Congress 2014 by Dr Maria Grazia Bongiorni, chair ... "The number of cardiac implantable electronic devices (CIED) implant ... technology the number of complications has increased and leads ...
Breaking Medicine News(10 mins):Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 3Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 4Health News:Expanding Care at the Forefront of Dermatology 2Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 3
... Biotech Group (USA), Inc.,(the "Company" or "Tiens", NYSE AlternextUS: ... for the twelve months ended,December 31, 2008. , ... 31, 2008, revenue was $77.2 million,an increase of 40.7% ... 31, 2007. , Net income ...
... John Lawson Cullison, Jr., an artist known for his work ... lost his ability to paint due to the effects of ... in cartilage tissue and symptoms include: pain, tenderness in the ... Pain management and joint replacement surgery are the typical ...
... for 21st century patient safety, says Dr. FriedbergCORONA ... Society of Anesthesiologists, (ASA) April ,Anesthesiology, reports of ... over medication (translation: ,TOO MUCH, anesthesia)," says Dr. ... brain activity monitors (BAMs), FDA approved and available ...
... new study in The Journal of Nursing Administration ... patients when continuous vigilance monitoring is used on medical-surgical ... Patrick Sullivan, President and CEO of Hoana Medical, Inc. ... RNs about potential patient deterioration so they can respond ...
... 31 , - ... and Smartphone,Applications , Elsevier, ... the winners in the Elsevier Article 2.0 Contest ... creative and useful solutions for rendering journal articles ...
... across North Carolina , ... Englewood, CO (Vocus) March ... science careers and information, unveiled the seventh edition of the ... ,This regional campaign is a promotional effort highlighting biotechnological, pharmaceutical and ...
Cached Medicine News:Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 2Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 3Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 4Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 5Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 6Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 7Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 8Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 9Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 10Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 11Health News:Tiens Biotech Group (USA) Reports Record Twelve-Month Results 12Health News:Korean Stem Cells Allow Artist to Paint Again 2Health News:American Society of Anesthesiologists - 2,211 Patient Deaths From OVER Medication 2Health News:Continuous Vigilance Monitoring Technology Benefits Nurses & Patients 2Health News:Three Prize Winners Awarded in Elsevier's Article 2.0 Contest 2Health News:Three Prize Winners Awarded in Elsevier's Article 2.0 Contest 3Health News:BioSpace Launches the 2009 Bio NC™ Hotbed Campaign 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: